Earnings ·
IN8bio, Inc. reported financial results for the second quarter ended June 30, 2026, on August 6, 2026
INABIN8Bio, Inc.
IN8bio, Inc. reported financial results for the second quarter ended June 30, 2026, on August 6, 2026. The company reported a net loss of $4.8 million, or $0.25 per share, compared to a net loss of $5.1 million in the prior year period. Cash and cash equivalents stood at $18.0 million as of June 30, 2026. Research and development expenses were $2.5 million, while general and administrative expenses decreased to $2.4 million from $2.7 million in the comparable prior year period. Clinically, IN8bio presented updated data at ASCO 2026 showing median overall survival exceeding 19.5 months for glioblastoma patients treated with DeltEx™ Drug Resistant Immunotherapy (DRI). The company also advanced its gamma-delta T cell engager platform, moving the CD19-targeting candidate INB-619 into IND-enabling studies and expecting initial in vivo data in the second half of 2026. IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies and engagers for cancer and autoimmune diseases.